The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The research target in the retrieved literature is human FBXO15 (F-box protein 15; also written FBX15), an F-box protein acting as a substrate-recruiting component of an SCF-type E3 ubiquitin ligase (Skp1–Cullin1–F-box). This matches the UniProt-provided description “F-box only protein 15” and the expected role of an F-box domain protein as a substrate receptor for SCF ubiquitin ligases. Primary studies explicitly refer to Skp1–Cullin1–FBXO15 / SCF^FBXO15 complexes and experimentally test FBXO15-dependent ubiquitination/degradation of multiple substrates (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 1-2, chen2014e3ligasesubunit pages 4-6).
SCF E3 ligases are a major class of Cullin-RING ubiquitin ligases in which CUL1 serves as a scaffold, SKP1 as an adaptor, RBX1/2 as the RING component, and an F-box protein provides substrate specificity by recognizing degrons in target proteins (tekcham2020fboxproteinsand pages 1-3). In this framework, FBXO15 is the variable F-box subunit proposed/validated to recruit particular substrates for polyubiquitination and 26S proteasome-mediated degradation (chen2014e3ligasesubunit pages 4-6, katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 5-7).
A recurrent principle in SCF biology is that substrates are frequently recruited via degrons that depend on post-translational modifications (e.g., phosphorylation, acetylation). For FBXO15-associated biology:
FBXO15 is not an enzyme that catalyzes a small-molecule reaction; its primary biochemical role is protein–protein interaction–mediated substrate recruitment to an SCF-type E3 ligase, enabling target protein polyubiquitination and proteasomal degradation.
A primary mechanistic study identified CLS1 as a substrate regulated by FBXO15 in the context of pneumonia and mitochondrial dysfunction. Key mechanistic points:
Functional consequences tied to substrate loss include reduced cardiolipin content, mitochondrial depolarization, and decreased ATP (chen2014e3ligasesubunit pages 4-6).
In cancer cells, FBXO15 was experimentally linked to post-translational control of the drug efflux transporter ABCB1:
This constitutes direct evidence that FBXO15 can regulate plasma-membrane transporter abundance via ubiquitin–proteasome pathway control (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5).
A 2021 study in breast cancer models provides mechanistic evidence that FBXO15 suppresses EMT/CSC phenotypes by degrading stemness/signaling factors:
This work supports FBXO15 as a substrate receptor that can directly reduce levels of transcriptional/signaling regulators (SOX2, STAT3) with major phenotypic consequences in cancer cells (zhao2021fbxo15playsa pages 1-3, zhao2021fbxo15playsa pages 3-4).
While not human-specific evidence, a high-quality mechanistic study in mouse ESCs provides a clear molecular paradigm for FBXO15 substrate recognition:
This provides a concrete “acetyldegron” mechanism that could be relevant to human FBXO15 substrate selection, though direct human validation is not established within the retrieved evidence (werner2017poweringstemcell pages 1-2).
In the CLS1 pathway, fractionation and mechanistic interpretation support that FBXO15 does not act inside mitochondria:
For SOX2/STAT3 and P-gp/ABCB1, the retrieved excerpts demonstrate ubiquitination/degradation and binding but do not cleanly resolve compartment-specific ubiquitination sites. However, the substrates themselves (SOX2, STAT3) function largely in transcriptional regulation and signaling, consistent with cytosolic/nuclear pools being relevant (zhao2021fbxo15playsa pages 1-3). Direct compartment assignment is strongest for the CLS1 ER-linked model (chen2014e3ligasesubunit pages 7-9).
FBXO15’s clearest pathway embedding is within:
Direct 2023–2024 primary mechanistic studies on human FBXO15 were limited in the retrieved corpus. The most actionable “recent” signals come from:
FBXO15’s regulation of ABCB1/P-gp provides a direct mechanistic link to drug efflux and chemotherapy response:
This suggests a potential translational angle: modulating an E3 substrate receptor (FBXO15) could alter ABCB1 abundance and affect multidrug resistance phenotypes (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5, katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 7-8).
FBXO15 has been implemented experimentally in in vivo pneumonia models:
These constitute real-world implementations in disease modeling and human tissue measurement (chen2014e3ligasesubunit pages 6-7, chen2014e3ligasesubunit pages 7-9).
Multiple breast cancer datasets and experiments support FBXO15 as a prognostic-associated factor:
High-authority reviews frame FBXO15 within broader F-box protein biology:
| Category | Protein class/domain | Complex | Validated substrates | Recognition/degron determinants | Subcellular localization/site of action | Biological processes | Disease/clinical links | Key quantitative/statistical findings | Key references with year/DOI |
|---|---|---|---|---|---|---|---|---|---|
| CLS1/PINK1 pneumonia axis | FBXO15 is an FBXO-family F-box substrate receptor in the ubiquitin-proteasome system (chen2014e3ligasesubunit pages 4-6, tekcham2020fboxproteinsand pages 1-3) | SCF^FBXO15; literature explicitly refers to an SCF^Fbxo15 complex targeting CLS1 (chen2014e3ligasesubunit pages 4-6, chen2014e3ligasesubunit pages 7-9) | Cardiolipin synthase 1 (CLS1) (chen2014e3ligasesubunit pages 2-4, chen2014e3ligasesubunit pages 4-6) | CLS1 aa ~200–250 docking region; Thr219 required for FBXO15 binding and acts as a PINK1-related phospho-recognition site; Lys174 is a ubiquitin acceptor, with K174R partially resistant to polyubiquitination and degradation (chen2014e3ligasesubunit pages 4-6, chen2014e3ligasesubunit pages 7-9) | FBXO15 was not detected in mitochondria; authors propose ubiquitination/degradation of CLS1 occurs in ER/cytosol after biosynthesis, limiting mitochondrial delivery of CLS1 (chen2014e3ligasesubunit pages 7-9) | Cardiolipin homeostasis, mitochondrial membrane potential, ATP production, lung injury responses in pneumonia (chen2014e3ligasesubunit pages 2-4, chen2014e3ligasesubunit pages 4-6, chen2014e3ligasesubunit pages 7-9) | Experimental pneumonia; human pneumonia lung tissue also examined for FBXO15/PINK1/CLS1 changes (chen2014e3ligasesubunit pages 6-7) | PINK1 overexpression decreased CLS1/cardiolipin/ATP; PINK1 knockdown increased CLS1/cardiolipin (p<0.05 for cardiolipin, p<0.01 for ATP); S. aureus pneumonia models used n=4 or n=6/group depending experiment; infection doses reported as 10^7 cfu/mouse at early time points and 10^5 cfu/mouse at 24 h; multiple physiologic endpoints significant at *p<0.05 (chen2014e3ligasesubunit pages 4-6, chen2014e3ligasesubunit pages 6-7, chen2014e3ligasesubunit pages 7-9) | Chen et al., 2014, Cell Reports, doi:10.1016/j.celrep.2014.02.048 (chen2014e3ligasesubunit pages 2-4, chen2014e3ligasesubunit pages 4-6) |
| ABCB1/P-gp drug resistance | FBXO15 functions as an F-box substrate receptor controlling membrane transporter abundance post-translationally (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5, katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 1-2) | Skp1-Cullin1-FBXO15 / SCF^Fbx15 with E2 Ube2r1/Cdc34 (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 1-2) | P-glycoprotein / ABCB1 / MDR1 (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5) | No degron residue mapped in the retrieved evidence; FBXO15 binds P-gp and promotes ubiquitination in cooperation with Ube2r1 (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5) | No compartment resolved in extracted text; ubiquitination demonstrated in cell lysates with MG132, consistent with proteasomal turnover of P-gp (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5) | Drug efflux regulation and multidrug resistance via control of P-gp protein stability, not MDR1 mRNA (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5, katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 5-7) | Cancer chemoresistance / vincristine sensitivity (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 5-7, katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 7-8) | Preliminary vincristine IC50 values: ~100 nM (HCT-15, HT1080/3HisMDR), 10 nM (SW620-14), 2 nM (HT1080); FBXO15 knockdown increased resistance to vincristine and reduced rhodamine-123 accumulation; VCR assay n=6, *P<0.002 (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 5-7, katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 7-8) | Katayama et al., 2013, Cancer Science, doi:10.1111/cas.12145 (katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5, katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 5-7) |
| SOX2/STAT3/EGFR breast cancer axis | FBXO15 acts as a tumor-suppressive F-box protein in breast cancer (zhao2021fbxo15playsa pages 1-3, huang2025fboxinbreast pages 6-7) | SCF-type role inferred from F-box identity; direct assays show FBXO15 interaction with SOX2 and STAT3 and promotion of their ubiquitination/degradation (zhao2021fbxo15playsa pages 1-3, zhao2021fbxo15playsa pages 3-4) | SOX2 and STAT3 are directly supported; EGFR is regulated downstream through SOX2 stabilization and signaling effects (zhao2021fbxo15playsa pages 1-3, zhao2021fbxo15playsa pages 3-4) | CHX pulse-chase, ubiquitination assays, co-IP and in situ assays support degradation of SOX2 and STAT3; no specific degron residue reported in extracted text (zhao2021fbxo15playsa pages 1-3, zhao2021fbxo15playsa pages 3-4) | Compartment not explicitly resolved in extracted text; IHC and in situ assays support tumor-cell expression and interactions (zhao2021fbxo15playsa pages 1-3) | Suppression of EMT and cancer stem-cell programs; inhibition of EGFR/ERK/STAT3 signaling; reduced growth, invasion, migration, sphere formation, anchorage-independent growth, xenograft burden and lung metastasis (zhao2021fbxo15playsa pages 1-3) | Breast cancer prognosis/biomarker potential; FBXO15 higher in normal tissue than IDC and higher in luminal than basal tumors; high expression associated with improved survival and independent disease-free survival association (zhao2021fbxo15playsa pages 1-3, zhao2021fbxo15playsa pages 3-4) | Orthotopic xenografts used n=5/group; qualitative survival benefit by Kaplan–Meier; no hazard ratio extracted from available text (zhao2021fbxo15playsa pages 3-4); mechanistic figure panels available for expression/survival/model (zhao2021fbxo15playsa media 5744e420, zhao2021fbxo15playsa media edf7edde, zhao2021fbxo15playsa media c6587a16) | Zhao et al., 2021, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00605-4 (zhao2021fbxo15playsa pages 1-3, zhao2021fbxo15playsa pages 3-4) |
| Stem cell mitochondrial biogenesis acetyl-degron | FBXO15 is a stem-cell-preferential F-box substrate adaptor; review/commentary explicitly places it in SCF complexes (werner2017poweringstemcell pages 1-2) | SCF^FBXO15 in mouse ESCs (werner2017poweringstemcell pages 1-2) | KBP/KIF1BP in mESCs (mouse evidence; useful for mechanistic inference, not direct human validation) (werner2017poweringstemcell pages 1-2) | Acetylation-dependent degron: GCN5L1 and TDH-driven mitochondrial acetyl-CoA promote KBP Lys501 acetylation, enabling recognition by Fbxo15; K→R mutation blocks degradation (werner2017poweringstemcell pages 1-2) | Fractionation evidence indicates compartmental regulation linked to mitochondrial biogenesis; retrieved review/commentary emphasizes mitochondrial metabolic coupling, though exact human localization is not established (werner2017poweringstemcell pages 1-2, donato2017thetdh–gcn5l1–fbxo15–kbpaxis pages 10-14) | Limits mitochondrial biogenesis in self-renewing ESCs; links metabolism, acetylation, ubiquitination, respiration, ROS, proliferation, and differentiation competence (werner2017poweringstemcell pages 1-2) | Stem-cell state marker and pluripotency-associated pathway; mainly developmental/stem-cell biology rather than direct human disease evidence in retrieved texts (werner2017poweringstemcell pages 1-2) | FBXO15 is preferentially expressed in undifferentiated cells and silenced at differentiation onset; stabilization of KBP increases mitochondrial mass, respiration and ROS, while ectopic FBXO15 impairs differentiation (werner2017poweringstemcell pages 1-2) | Donato et al., 2017, Nature Cell Biology, doi:10.1038/ncb3491; Werner & Rape, 2017, Cell Death Differ., doi:10.1038/cdd.2017.142 (werner2017poweringstemcell pages 1-2) |
| Expression in breast cancer datasets | FBXO15 is part of an SCF/F-box transcriptional signature in breast cancer datasets (chang2021anovelsignature pages 2-5) | Not a mechanistic complex study; expression profiling context (chang2021anovelsignature pages 2-5) | Not applicable | Not applicable | Tissue/tumor expression by RNA-seq, TCGA and IHC (chang2021anovelsignature pages 2-5, chang2021anovelsignature pages 7-10) | Tumor-associated expression program; possible biomarker/signature component (chang2021anovelsignature pages 2-5, chang2021anovelsignature pages 7-10) | Breast carcinoma profiling/signature studies (chang2021anovelsignature pages 2-5, chang2021anovelsignature pages 7-10) | FBXO15 mRNA increased up to 7.7-fold in paired breast carcinoma vs normal tissue; protein elevated ~3.6–5.2-fold across BRCA stages 0–IV vs normal (p<0.001); mRNA increased in MCF7 and MDA-MB231 vs MCF10A (p<0.001); ~89% knockdown had no detectable effect on viability/proliferation in that assay context (chang2021anovelsignature pages 2-5, chang2021anovelsignature pages 7-10) | Chang et al., 2021, Cancers, doi:10.3390/cancers13122873 (chang2021anovelsignature pages 2-5, chang2021anovelsignature pages 7-10) |
| General SCF/F-box definition | F-box proteins are substrate receptors; SCF contains SKP1 adaptor, CUL1 scaffold, RBX1/2 RING protein, plus variable F-box protein; FBXO subfamily are “F-box only” proteins lacking LRR/WD40 repeat classes (tekcham2020fboxproteinsand pages 1-3) | Canonical SCF (SKP1-CUL1-RBX1/2-F-box) (tekcham2020fboxproteinsand pages 1-3) | Not applicable | Many SCF substrates require post-translationally generated degrons; FBXO15-specific examples include phospho- and acetyldegron recognition from other rows (chen2014e3ligasesubunit pages 4-6, werner2017poweringstemcell pages 1-2, tekcham2020fboxproteinsand pages 1-3) | Ubiquitin-proteasome system; compartment varies by substrate (tekcham2020fboxproteinsand pages 1-3) | Protein homeostasis, signaling, cell cycle, differentiation, stress responses, cancer biology (tekcham2020fboxproteinsand pages 1-3) | Framework for interpreting FBXO15 as a substrate-recognition module in disease pathways (tekcham2020fboxproteinsand pages 1-3) | Review notes ~37 human FBXO-family members (tekcham2020fboxproteinsand pages 1-3) | Tekcham et al., 2020, Theranostics, doi:10.7150/thno.42735 (tekcham2020fboxproteinsand pages 1-3) |
| OpenTargets GWAS credible sets | Human FBXO15 is recognized as an approved target/gene entity in Open Targets (ENSG00000141665) (OpenTargets Search: -FBXO15) | Not a mechanistic protein complex entry | Not applicable | Not applicable | Genetics/association layer rather than localization data (OpenTargets Search: -FBXO15) | Suggests possible roles in complex traits/disease susceptibility but not mechanism (OpenTargets Search: -FBXO15) | Reported associations include bacterial disease, body weight gain, smoking initiation, Abruptio Placentae, and glomerulonephritis (OpenTargets Search: -FBXO15) | Open Targets scores: bacterial disease 0.3129; Abruptio Placentae 0.3000; body weight gain 0.2461; glomerulonephritis 0.1654; smoking initiation 0.1477. Evidence count=4, from GWAS credible sets; cited PMIDs include 40770095, 40069456, 39024449, but effect sizes were not available in retrieved context (OpenTargets Search: -FBXO15) | Open Targets Platform query (context evidence generated from current platform output; article cited by platform: Buniello et al., 2025, Nucleic Acids Res.) (OpenTargets Search: -FBXO15) |
Table: This table summarizes experimentally supported functions, substrates, mechanisms, localization, and disease relevance of human FBXO15, with emphasis on primary mechanistic studies and recent genetic-association context. It is designed as a compact evidence map for interpreting FBXO15 as an SCF-type F-box substrate receptor.
A representative set of cropped figure panels from Zhao et al. (2021) illustrating (i) FBXO15 expression/survival association, (ii) IHC relationship with SOX2/EGFR, and (iii) a mechanistic model of the FBXO15–SOX2/STAT3/EGFR axis were retrieved (zhao2021fbxo15playsa media 5744e420, zhao2021fbxo15playsa media edf7edde, zhao2021fbxo15playsa media c6587a16).
References
(katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 1-2): Kazuhiro Katayama, Kohji Noguchi, and Yoshikazu Sugimoto. Fbxo15 regulates p‐glycoprotein/abcb1 expression through the ubiquitin–proteasome pathway in cancer cells. Cancer Science, 104:694-702, Jun 2013. URL: https://doi.org/10.1111/cas.12145, doi:10.1111/cas.12145. This article has 77 citations and is from a peer-reviewed journal.
(chen2014e3ligasesubunit pages 4-6): Bill B. Chen, Tiffany A. Coon, Jennifer R. Glasser, Chunbin Zou, Bryon Ellis, Tuhin Das, Alison C. McKelvey, Shristi Rajbhandari, Travis Lear, Christelle Kamga, Sruti Shiva, Chenjian Li, Joseph M. Pilewski, Jason Callio, Charleen T. Chu, Anuradha Ray, Prabir Ray, Yulia Y. Tyurina, Valerian E. Kagan, and Rama K. Mallampalli. E3 ligase subunit fbxo15 and pink1 kinase regulate cardiolipin synthase 1 stability and mitochondrial function in pneumonia. Cell reports, 7:476-487, Apr 2014. URL: https://doi.org/10.1016/j.celrep.2014.02.048, doi:10.1016/j.celrep.2014.02.048. This article has 57 citations and is from a highest quality peer-reviewed journal.
(tekcham2020fboxproteinsand pages 1-3): Dinesh Singh Tekcham, Di Chen, Yu Liu, Ting Ling, Yi Zhang, Huan Chen, Wen Wang, Wuxiyar Otkur, Huan Qi, Tian Xia, Xiaolong Liu, Hai-long Piao, and Hongxu Liu. F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Theranostics, 10:4150-4167, Mar 2020. URL: https://doi.org/10.7150/thno.42735, doi:10.7150/thno.42735. This article has 111 citations and is from a domain leading peer-reviewed journal.
(katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 5-7): Kazuhiro Katayama, Kohji Noguchi, and Yoshikazu Sugimoto. Fbxo15 regulates p‐glycoprotein/abcb1 expression through the ubiquitin–proteasome pathway in cancer cells. Cancer Science, 104:694-702, Jun 2013. URL: https://doi.org/10.1111/cas.12145, doi:10.1111/cas.12145. This article has 77 citations and is from a peer-reviewed journal.
(chen2014e3ligasesubunit pages 7-9): Bill B. Chen, Tiffany A. Coon, Jennifer R. Glasser, Chunbin Zou, Bryon Ellis, Tuhin Das, Alison C. McKelvey, Shristi Rajbhandari, Travis Lear, Christelle Kamga, Sruti Shiva, Chenjian Li, Joseph M. Pilewski, Jason Callio, Charleen T. Chu, Anuradha Ray, Prabir Ray, Yulia Y. Tyurina, Valerian E. Kagan, and Rama K. Mallampalli. E3 ligase subunit fbxo15 and pink1 kinase regulate cardiolipin synthase 1 stability and mitochondrial function in pneumonia. Cell reports, 7:476-487, Apr 2014. URL: https://doi.org/10.1016/j.celrep.2014.02.048, doi:10.1016/j.celrep.2014.02.048. This article has 57 citations and is from a highest quality peer-reviewed journal.
(werner2017poweringstemcell pages 1-2): Achim Werner and Michael Rape. Powering stem cell decisions with ubiquitin. Cell Death and Differentiation, 24:1823-1824, Sep 2017. URL: https://doi.org/10.1038/cdd.2017.142, doi:10.1038/cdd.2017.142. This article has 3 citations and is from a domain leading peer-reviewed journal.
(chen2014e3ligasesubunit pages 2-4): Bill B. Chen, Tiffany A. Coon, Jennifer R. Glasser, Chunbin Zou, Bryon Ellis, Tuhin Das, Alison C. McKelvey, Shristi Rajbhandari, Travis Lear, Christelle Kamga, Sruti Shiva, Chenjian Li, Joseph M. Pilewski, Jason Callio, Charleen T. Chu, Anuradha Ray, Prabir Ray, Yulia Y. Tyurina, Valerian E. Kagan, and Rama K. Mallampalli. E3 ligase subunit fbxo15 and pink1 kinase regulate cardiolipin synthase 1 stability and mitochondrial function in pneumonia. Cell reports, 7:476-487, Apr 2014. URL: https://doi.org/10.1016/j.celrep.2014.02.048, doi:10.1016/j.celrep.2014.02.048. This article has 57 citations and is from a highest quality peer-reviewed journal.
(katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 3-5): Kazuhiro Katayama, Kohji Noguchi, and Yoshikazu Sugimoto. Fbxo15 regulates p‐glycoprotein/abcb1 expression through the ubiquitin–proteasome pathway in cancer cells. Cancer Science, 104:694-702, Jun 2013. URL: https://doi.org/10.1111/cas.12145, doi:10.1111/cas.12145. This article has 77 citations and is from a peer-reviewed journal.
(katayama2013fbxo15regulatesp‐glycoproteinabcb1 pages 7-8): Kazuhiro Katayama, Kohji Noguchi, and Yoshikazu Sugimoto. Fbxo15 regulates p‐glycoprotein/abcb1 expression through the ubiquitin–proteasome pathway in cancer cells. Cancer Science, 104:694-702, Jun 2013. URL: https://doi.org/10.1111/cas.12145, doi:10.1111/cas.12145. This article has 77 citations and is from a peer-reviewed journal.
(zhao2021fbxo15playsa pages 1-3): Yi Zhao, Nayeon Shim, Yan-Hong Cui, Jae-Hyeok Kang, Ki-Chun Yoo, Seungmo Kim, Joo Mi Yi, Min-Jung Kim, Jai Hoon Yoon, and Su-Jae Lee. Fbxo15 plays a critical suppressive functional role in regulation of breast cancer progression. Signal Transduction and Targeted Therapy, Jun 2021. URL: https://doi.org/10.1038/s41392-021-00605-4, doi:10.1038/s41392-021-00605-4. This article has 8 citations and is from a peer-reviewed journal.
(zhao2021fbxo15playsa pages 3-4): Yi Zhao, Nayeon Shim, Yan-Hong Cui, Jae-Hyeok Kang, Ki-Chun Yoo, Seungmo Kim, Joo Mi Yi, Min-Jung Kim, Jai Hoon Yoon, and Su-Jae Lee. Fbxo15 plays a critical suppressive functional role in regulation of breast cancer progression. Signal Transduction and Targeted Therapy, Jun 2021. URL: https://doi.org/10.1038/s41392-021-00605-4, doi:10.1038/s41392-021-00605-4. This article has 8 citations and is from a peer-reviewed journal.
(OpenTargets Search: -FBXO15): Open Targets Query (-FBXO15, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(chen2014e3ligasesubunit pages 6-7): Bill B. Chen, Tiffany A. Coon, Jennifer R. Glasser, Chunbin Zou, Bryon Ellis, Tuhin Das, Alison C. McKelvey, Shristi Rajbhandari, Travis Lear, Christelle Kamga, Sruti Shiva, Chenjian Li, Joseph M. Pilewski, Jason Callio, Charleen T. Chu, Anuradha Ray, Prabir Ray, Yulia Y. Tyurina, Valerian E. Kagan, and Rama K. Mallampalli. E3 ligase subunit fbxo15 and pink1 kinase regulate cardiolipin synthase 1 stability and mitochondrial function in pneumonia. Cell reports, 7:476-487, Apr 2014. URL: https://doi.org/10.1016/j.celrep.2014.02.048, doi:10.1016/j.celrep.2014.02.048. This article has 57 citations and is from a highest quality peer-reviewed journal.
(zhao2021fbxo15playsa media 5744e420): Yi Zhao, Nayeon Shim, Yan-Hong Cui, Jae-Hyeok Kang, Ki-Chun Yoo, Seungmo Kim, Joo Mi Yi, Min-Jung Kim, Jai Hoon Yoon, and Su-Jae Lee. Fbxo15 plays a critical suppressive functional role in regulation of breast cancer progression. Signal Transduction and Targeted Therapy, Jun 2021. URL: https://doi.org/10.1038/s41392-021-00605-4, doi:10.1038/s41392-021-00605-4. This article has 8 citations and is from a peer-reviewed journal.
(zhao2021fbxo15playsa media edf7edde): Yi Zhao, Nayeon Shim, Yan-Hong Cui, Jae-Hyeok Kang, Ki-Chun Yoo, Seungmo Kim, Joo Mi Yi, Min-Jung Kim, Jai Hoon Yoon, and Su-Jae Lee. Fbxo15 plays a critical suppressive functional role in regulation of breast cancer progression. Signal Transduction and Targeted Therapy, Jun 2021. URL: https://doi.org/10.1038/s41392-021-00605-4, doi:10.1038/s41392-021-00605-4. This article has 8 citations and is from a peer-reviewed journal.
(wang2014rolesoffbox pages 11-13): Zhiwei Wang, Pengda Liu, Hiroyuki Inuzuka, and Wenyi Wei. Roles of f-box proteins in cancer. Nature Reviews Cancer, 14:233-247, Mar 2014. URL: https://doi.org/10.1038/nrc3700, doi:10.1038/nrc3700. This article has 586 citations and is from a domain leading peer-reviewed journal.
(chang2021anovelsignature pages 7-10): Shu-Chun Chang, Chin-Sheng Hung, Bo-Xiang Zhang, Tsung-Han Hsieh, Wayne Hsu, and Jeak Ding. A novel signature of ccnf-associated e3 ligases collaborate and counter each other in breast cancer. Cancers, 13:2873, Jun 2021. URL: https://doi.org/10.3390/cancers13122873, doi:10.3390/cancers13122873. This article has 23 citations.
(chang2021anovelsignature pages 2-5): Shu-Chun Chang, Chin-Sheng Hung, Bo-Xiang Zhang, Tsung-Han Hsieh, Wayne Hsu, and Jeak Ding. A novel signature of ccnf-associated e3 ligases collaborate and counter each other in breast cancer. Cancers, 13:2873, Jun 2021. URL: https://doi.org/10.3390/cancers13122873, doi:10.3390/cancers13122873. This article has 23 citations.
(huang2025fboxinbreast pages 6-7): Qi-yan Huang, Ye Ma, Wen-yi Sheng, Shi-qi Liu, Jia-le Cheng, Wen-jie Wang, and You Meng. F-box in breast cancer: mechanism of action and therapeutic potential. American Journal of Translational Research, 17:8203-8221, Jan 2025. URL: https://doi.org/10.62347/devn4395, doi:10.62347/devn4395. This article has 0 citations and is from a peer-reviewed journal.
(zhao2021fbxo15playsa media c6587a16): Yi Zhao, Nayeon Shim, Yan-Hong Cui, Jae-Hyeok Kang, Ki-Chun Yoo, Seungmo Kim, Joo Mi Yi, Min-Jung Kim, Jai Hoon Yoon, and Su-Jae Lee. Fbxo15 plays a critical suppressive functional role in regulation of breast cancer progression. Signal Transduction and Targeted Therapy, Jun 2021. URL: https://doi.org/10.1038/s41392-021-00605-4, doi:10.1038/s41392-021-00605-4. This article has 8 citations and is from a peer-reviewed journal.
(donato2017thetdh–gcn5l1–fbxo15–kbpaxis pages 10-14): Valerio Donato, Massimo Bonora, Daniele Simoneschi, Davide Sartini, Yasusei Kudo, Anita Saraf, Laurence Florens, Michael P. Washburn, Matthias Stadtfeld, Paolo Pinton, and Michele Pagano. The tdh–gcn5l1–fbxo15–kbp axis limits mitochondrial biogenesis in mouse embryonic stem cells. Nature Cell Biology, 19(4):341-351, Mar 2017. URL: https://doi.org/10.1038/ncb3491, doi:10.1038/ncb3491. This article has 60 citations and is from a highest quality peer-reviewed journal.